Literature DB >> 24249427

Antifungal prophylaxis following allogeneic haematopoietic stem cell transplantation: what is the role of voriconazole?

M Hoenigl1, K Seeber, R Krause.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24249427     DOI： 10.1007/s15010-013-0562-4

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  5 in total

Review 1.  Antifungal prophylaxis in haematology patients: the role of voriconazole.

Authors:  Y Hicheri; G Cook; C Cordonnier
Journal:  Clin Microbiol Infect       Date:  2012-04       Impact factor: 8.067

2.  Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies.

Authors:  Martin Hoenigl; Wiebke Duettmann; Reinhard B Raggam; Katharina Seeber; Katharina Troppan; Sonja Fruhwald; Florian Prueller; Jasmin Wagner; Thomas Valentin; Ines Zollner-Schwetz; Albert Wölfler; Robert Krause
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

3.  Impact of galactomannan testing on the prevalence of invasive aspergillosis in patients with hematological malignancies.

Authors:  Martin Hoenigl; Helmut J F Salzer; Reinhard B Raggam; Thomas Valentin; Angelika Rohn; Albert Woelfler; Katharina Seeber; Werner Linkesch; Robert Krause
Journal:  Med Mycol       Date:  2011-09-12       Impact factor: 4.076

4.  Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants.

Authors:  Kieren A Marr; Fulvio Crippa; Wendy Leisenring; Maggie Hoyle; Michael Boeckh; S Arunmozhi Balajee; W Garrett Nichols; Benjamin Musher; Lawrence Corey
Journal:  Blood       Date:  2003-10-02       Impact factor: 22.113

5.  Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.

Authors:  David I Marks; Antonio Pagliuca; Christopher C Kibbler; Axel Glasmacher; Claus-Peter Heussel; Michal Kantecki; Paul J S Miller; Patricia Ribaud; Haran T Schlamm; Carlos Solano; Gordon Cook
Journal:  Br J Haematol       Date:  2011-08-22       Impact factor: 6.998
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.